B+
Bull case
20%
Probability
Target price
$99.85
+62.2% vs current
TARS
TarsusDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-11
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$87.87
+42.8% vs current
B-
Bear case
20%
Probability
Target price
$55.92
-9.1% vs current
AI sentiment snapshot
Latest data as of 2026-01-07
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+80.7
Score
AI commentary
Consensus targets cluster in the mid-$80s; the base case implies modest upside versus the anchor. Market tone is cautiously constructive—commercial execution and recent sales support upside, while insider selling and binary clinical outcomes keep near-term sentiment fragile. Key near-term drivers: earnings/guidance and clinical readouts.
RankAlpha Sentiment AI - 2026-01-07
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-04-07catalystNext quarterly earnings / guidanceHigh impact
Upcoming quarterly results and management guidance can drive near-term sentiment; analysts' 12-month targets show dispersion around the anchor, which may amplify moves on surprise results [#SERP-1].
2026-09-30eventPivotal clinical readout for lead ophthalmic candidateHigh impact
A positive Phase 3 readout would materially re-rate valuation; timeline uncertain so using a conservative assumed window end for planning purposes (assumed end of Sept 2026) [#SERP-3].
2027-01-07catalystCommercial launch and uptake expansionHigh impact
Wider commercial rollout and reimbursement progress would support longer-term multiple expansion; gradual realization expected over the next year [#SERP-2].
Recommendation
N/A
No formal recommendation provided.
As of 2026-01-07 • Updated nightlySource: Internal modelMethodology